A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02154425
- Locations
- 🇳🇱
501, Rotterdam, Netherlands
🇺🇸7, Los Angeles, California, United States
🇳🇱500, Maastricht, Netherlands
Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT02088957
- Locations
- 🇺🇸
1, Jackson, Mississippi, United States
🇺🇸3, Lexington, Kentucky, United States
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
- Conditions
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02019602
- Locations
- 🇫🇷
200, Paris, France
🇺🇸9, Oklahoma City, Oklahoma, United States
🇫🇷203, Lille, France
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT01964560
- Locations
- 🇵🇱
Ep0034 431, Krakow, Poland
🇵🇱Ep0034 422, Krakow, Poland
🇵🇱Ep0034 433, Gdansk, Poland
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT01533714
- Locations
- 🇨🇳
309, Taipei, Taiwan
🇨🇳302, Taipei, Taiwan
🇨🇳308, Taipei, Taiwan
Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01498120
- Locations
- 🇺🇸
012, Los Angeles, California, United States
🇺🇸001, Destrehan, Louisiana, United States
🇺🇸013, Indianapolis, Indiana, United States
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01495793
- Locations
- 🇺🇸
Sp1004 012, Los Angeles, California, United States
🇺🇸Sp1004 007, West Seneca, New York, United States
🇺🇸Sp1004 013, Indianapolis, Indiana, United States
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 767
- Registration Number
- NCT01339559
- Locations
- 🇺🇸
064, Port Charlotte, Florida, United States
🇺🇸011, Dallas, Texas, United States
🇺🇸778, Columbus, Ohio, United States
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 190
- Registration Number
- NCT01296711
- Locations
- 🇺🇸
126, Houston, Texas, United States
🇺🇸132, Houston, Texas, United States
🇺🇸138, Houston, Texas, United States
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01118949